Courtesy of the SBHCI. There is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy. The NOTION study aims at comparing<a href="https://solaci.org/en/2017/05/30/notion-tavi-with-low-risk-at-4-year-follow-up/" title="Read more" >...</a>
Courtesy of the SBHCI. Bioprosthetic surgically-implanted valves degenerate over time, while patients become too old and are at high risk for reoperation. Transcatheter aortic valve implantation inside a deteriorated surgically-implanted valve (a valve-in-valve procedure) is an emerging alternative. The VIVA trial was designed to offer systematic and prospective data from patients treated with<a href="https://solaci.org/en/2017/05/30/viva-post-market-study-more-evidence-for-the-valve-in-valve-technique/" title="Read more" >...</a>
This new device offers the advantage of a lower frame height, which reduces the chance of coronary occlusion. The delivery system is totally motorized and the valve can be repositioned. In addition, the sheath is “14 F” for all valve sizes (23, 26 and 29mm). 203 patients were included, all with severe aortic stenosis<a href="https://solaci.org/en/2017/05/25/centera-results-of-the-new-self-expandable-valve/" title="Read more" >...</a>
Courtesy of Dr. Gustavo Leiva. Transcatheter aortic-valve replacement (TAVR) with the use of a self-expanding prosthesis is superior to medical therapy in patients with severe, symptomatic aortic stenosis in whom surgical aortic-valve replacement has been associated with prohibitive risk. Among patients considered at high risk, TAVR may be an alternative to surgery. The comparative<a href="https://solaci.org/en/2017/04/06/surgery-or-tavr-in-intermediate-risk-results-of-the-surtavi-study/" title="Read more" >...</a>
Two recent articles featured in JACC Cardiovascular Interventions showed that short term (at 30 days) outcomes of patients treated with the next-generation self-expanding Medtronic Evolut R valves could present several advantages compared to the original CoreValve, including recapturability. Both analyses reported similar rates of all-cause mortality and stroke. The study carried out by Dr. Jeffrey Popma as<a href="https://solaci.org/en/2017/02/23/evolut-r-clinical-results-might-be-better-than-those-for-first-generation-corevalve/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet. The study examined 782 patients with severe aortic stenosis who underwent<a href="https://solaci.org/en/2017/02/14/tavr-reasons-to-consider-mitral-annular-calcification/" title="Read more" >...</a>
We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin<a href="https://solaci.org/en/2017/01/07/see-the-presentations-of-the-2016-chile-sessions/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Between 40% and 70% of patients undergoing transcatheter aortic valve replacement (TAVR) present coronary lesions. The fact that aortic stenosis affects how blockages act, and that, after stenosis correction, hemodynamic compromise for those same lesions may vary, has been consistently proven. Its management has not been determined yet. The study<a href="https://solaci.org/en/2016/12/13/coronary-lesions-after-tavr-severity-may-be-modified/" title="Read more" >...</a>
New findings from the GARY (German Aortic Valve Registry) registry show that intermediate-risk patients with severe aortic stenosis presented significantly higher mortality at 1 year when treated with transcatheter aortic valve replacement (TAVR) rather than with conventional surgery. Results reflect everyday realities, which might include various bias tipping the scales towards one strategy or the<a href="https://solaci.org/en/2016/12/01/tavr-or-surgery-for-intermediate-risk-patients-gary-registry/" title="Read more" >...</a>
The introduction of transcatheter aortic valve replacement procedures (TAVR) seems to have increased the number of elderly patients hospitalized with severe aortic stenosis, as well as the number of interventions. However, less than one fifth of patients over 85 are intervened, according to a Canadian registry. Given the significant difference in mortality with TAVR,<a href="https://solaci.org/en/2016/11/30/less-than-20-of-patients-that-could-benefit-from-tavr-are-receiving-it/" title="Read more" >...</a>